ELF3 Plays an Important Role in Defining TRAIL Sensitivity in Breast Cancer by Modulating the Expression of Decoy Receptor 2 (DCR2)

ELF3 overexpression in breast cancer cells caused reversal of TRAIL resistance as observed using cell viability assay and cleaved caspase-3 immunoblotting.